These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 34132212)

  • 1. The complex and constantly evolving public health threat of new psychoactive substances in Italy: addressing the main functions of a national observatory of drugs.
    Graziano S; Zaami S; Tittarelli R; Pichini S; Sciotti M; Berretta P; Busardò FP; Marinelli E; Tini A; Scaravaggi G; Buscaglia E; Brambilla E; Cavallo M; Locatelli CA; Pacifici R; Varì MR
    Ann Ist Super Sanita; 2021; 57(2):144-150. PubMed ID: 34132212
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Responding to New Psychoactive Substances in the European Union: Early Warning, Risk Assessment, and Control Measures.
    Evans-Brown M; Sedefov R
    Handb Exp Pharmacol; 2018; 252():3-49. PubMed ID: 30194542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fighting trafficking of falsified and substandard medicinal products in Russia.
    Fayzrakhmanov NF
    Int J Risk Saf Med; 2015; 27 Suppl 1():S37-40. PubMed ID: 26639702
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Psychoactive Substances: Evolution in the Exchange of Information and Innovative Legal Responses in the European Union.
    Varì MR; Mannocchi G; Tittarelli R; Campanozzi LL; Nittari G; Feola A; Umani Ronchi F; Ricci G
    Int J Environ Res Public Health; 2020 Nov; 17(22):. PubMed ID: 33238595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New psychoactive substances: concerted efforts and common legislative answers for stemming a growing health hazard.
    Zaami S
    Eur Rev Med Pharmacol Sci; 2019 Nov; 23(22):9681-9690. PubMed ID: 31799633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monitoring new psychoactive substances: Exploring the contribution of an online discussion forum.
    Rhumorbarbe D; Morelato M; Staehli L; Roux C; Jaquet-Chiffelle DO; Rossy Q; Esseiva P
    Int J Drug Policy; 2019 Nov; 73():273-280. PubMed ID: 30967328
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The drug situation in Europe: an overview of data available on illicit drugs and new psychoactive substances from European monitoring in 2015.
    Mounteney J; Griffiths P; Sedefov R; Noor A; Vicente J; Simon R
    Addiction; 2016 Jan; 111(1):34-48. PubMed ID: 26419329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The challenge of a ban on animal testing for the development of a regulated legal market for new psychoactive substances (NPS) ('legal highs') in New Zealand: Issues and options for resolution.
    Rychert M; Wilkins C
    Int J Drug Policy; 2015 Dec; 26(12):1273-8. PubMed ID: 26364077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping novel psychoactive substances policy in the EU: The case of Portugal, the Netherlands, Czech Republic, Poland, the United Kingdom and Sweden.
    Neicun J; Steenhuizen M; van Kessel R; Yang JC; Negri A; Czabanowska K; Corazza O; Roman-Urrestarazu A
    PLoS One; 2019; 14(6):e0218011. PubMed ID: 31242225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Promoting innovation and excellence to face the rapid diffusion of novel psychoactive substances in the EU: the outcomes of the ReDNet project.
    Corazza O; Assi S; Simonato P; Corkery J; Bersani FS; Demetrovics Z; Stair J; Fergus S; Pezzolesi C; Pasinetti M; Deluca P; Drummond C; Davey Z; Blaszko U; Moskalewicz J; Mervo B; Furia LD; Farre M; Flesland L; Pisarska A; Shapiro H; Siemann H; Skutle A; Sferrazza E; Torrens M; Sambola F; van der Kreeft P; Scherbaum N; Schifano F
    Hum Psychopharmacol; 2013 Jul; 28(4):317-23. PubMed ID: 23881879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Legal aspects of counteracting the trafficking of falsified medicines in the european union.
    Pashkov V; Soloviov A; Olefir A
    Wiad Lek; 2017; 70(4):843-849. PubMed ID: 29064815
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New Psychoactive Substances: A Matter of Time.
    Pantano F; Graziano S; Pacifici R; Busardò FP; Pichini S
    Curr Neuropharmacol; 2019; 17(9):818-822. PubMed ID: 31577198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New psychoactive substances as adulterants of controlled drugs. A worrying phenomenon?
    Giné CV; Espinosa IF; Vilamala MV
    Drug Test Anal; 2014; 6(7-8):819-24. PubMed ID: 24470121
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New psychoactive substances: Are there any good options for regulating new psychoactive substances?
    Reuter P; Pardo B
    Int J Drug Policy; 2017 Feb; 40():117-122. PubMed ID: 27889115
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmaceutical Regulatory Framework in Ethiopia: A Critical Evaluation of Its Legal Basis and Implementation.
    Suleman S; Woliyi A; Woldemichael K; Tushune K; Duchateau L; Degroote A; Vancauwenberghe R; Bracke N; De Spiegeleer B
    Ethiop J Health Sci; 2016 May; 26(3):259-76. PubMed ID: 27358547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Collaboration of the Joint Research Centre and European Customs Laboratories for the Identification of New Psychoactive Substances.
    Guillou C; Reniero F; Lobo Vicente J; Holland M; Kolar K; Chassaigne H; Tirendi S; Schepers H
    Curr Pharm Biotechnol; 2018; 19(2):91-98. PubMed ID: 29792142
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A critical first assessment of the new pre-market approval regime for new psychoactive substances (NPS) in New Zealand.
    Wilkins C
    Addiction; 2014 Oct; 109(10):1580-6. PubMed ID: 24529166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of legislative management for new psychoactive substances control among Taiwan, South Korea, and Japan.
    Feng LY; Wada K; Chung H; Han E; Li JH
    Kaohsiung J Med Sci; 2020 Feb; 36(2):135-142. PubMed ID: 31643137
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Emergence, Diversity, and Control of New Psychoactive Substances: A Global Perspective.
    Tettey JNA; Crean C; Ifeagwu SC; Raithelhuber M
    Handb Exp Pharmacol; 2018; 252():51-67. PubMed ID: 29896655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Understanding the development of a regulated market approach to new psychoactive substances (NPS) in New Zealand using Punctuated Equilibrium Theory.
    Rychert M; Wilkins C
    Addiction; 2018 Nov; 113(11):2132-2139. PubMed ID: 29744945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.